值得关注的生物技术两用性研究的风险管理工具构建研究

Development of a risk management tool for Dual-use research of concern in biotechnology

  • 摘要:
    目的 构建适用于中国国情的值得关注的生物技术两用性研究风险管理工具,以填补两用性生物技术生物安全风险精细化管理工具的空白,推动生物安全监管模式从“事后应对”向“事前预防”转型。
    方法 通过系统梳理国内外相关政策法规与文献,运用“能力-意图-后果”框架构建值得关注的生物技术两用性研究风险识别决策树;结合ISO 31000风险管理框架、系统科学与负责任创新理论,建立风险评估指标体系;设计涵盖项目负责人自查与机构审查的审查流程;最后,通过典型案例对体系进行验证。
    结果 构建了集“快速筛查(决策树)、精准评估(风险评估指标体系)和规范流程(审查机制)”于一体的风险管理工具:决策树可明确界定值得关注的生物技术两用性研究;风险评估指标体系包含6个一级指标、30个二级指标,可将两用性研究划分为低(0-10分)、中(11-20分)、高(21-30分)三个风险等级;审查流程明确了各责任方的具体工作要求。经H5N1病毒功能获得性研究、脊髓灰质炎病毒合成研究、工程化大肠杆菌生产人胰岛素研究等典型案例验证,该体系具有良好的敏感性、区分度与特异性。
    结论 本研究构建的值得关注的生物技术两用性研究风险管理工具体系具有理论依据与实践价值,可为我国两用性生物技术生物安全的监管审查提供科学的决策支持,有助于提升我国生物安全治理能力。

     

    Abstract:
    Objectives To construct a risk management tool for Dual-Use Research of Concern (DURC) in biotechnology that is applicable to China's context, aiming to fill the gap in refined regulatory tools of dual use biotechnology biosafety risk and promote the transformation of the regulatory paradigm from reactive response to proactive prevention.
    Methods Through a systematic review of relevant domestic and international policies, regulations, and literature, a decision tree model for identifying DURC in biotechnology was developed based on the “Capability-Intent-Consequences” framework. Integrating the ISO 31000 risk management framework with systems science and Responsible Research and Innovation theory, a risk assessment indicator system comprising multi-level indicators was established. Subsequently, a standardized review mechanism encompassing project leader self-assessment and institutional review was designed.
    Results An integrated risk management tool, combining “rapid screening (decision tree), precise assessment (indicator system), standardized process (review mechanism)” was developed. The decision tree can clearly determine whether a research qualifies as DURC in biotechnology. The risk assessment system, comprising 6 first-level indicators and 30 second-level indicators, categorizes DURC in biotechnology into three risk levels: low (0-10 points), medium (11-20 points), and high (21-30 points). The review mechanism specifies the specific requirements for all responsible parties. Validation through typical cases, such as H5N1 gain-of-function research, poliovirus synthesis and production of human insulin by engineered Escherichia coli demonstrated that the system possesses good sensitivity, discrimination, and specificity.
    Conclusion The risk management tool system of DURC in biotechnology constructed in this study offers both theoretical basis and practical value, providing scientific decision support for the regulatory review of dual use biotechnology biosafety risk in China and contributing to the enhancement of governance capabilities.

     

/

返回文章
返回